deltatrials
Completed PHASE2 INTERVENTIONAL 5-arm NCT02196077

Efficacy and Safety Study of PT009, PT008, and PT005 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (PT009001)

A Randomized, Double Blind, Chronic Dosing (28 Days), Four Period, Five Treatment, Incomplete Block, Multi Center, Crossover Study to Assess the Efficacy and Safety of PT009, PT008, and PT005 in Subjects With Moderate to Severe COPD

Sponsor: Pearl Therapeutics, Inc.

Updated 8 times since 2017 Last updated: May 23, 2018 Started: Aug 1, 2014 Primary completion: Mar 1, 2015 Completion: Mar 1, 2015
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02196077, this PHASE2 trial focuses on Chronic Obstructive Pulmonary Disease and remains completed. Sponsored by Pearl Therapeutics, Inc., it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshotCompleted~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotCompleted~Jul 2018 – ~Jan 2021 · 30 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 24 months · monthly snapshotCompleted

Change History

8 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jul 2018 — Jan 2021 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

Show 3 earlier versions
  1. Jul 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jul 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Pearl Therapeutics, Inc.
Data source: Pearl Therapeutics, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .